Premium
The effect of two beta‐adrenoceptor blockers (mepindolol and atenolol) on blood lipids and platelet aggregation in normal volunteers and essential hypertensive patients.
Author(s) -
Luque Otero M,
Fernandez Pinilla C,
Escriba Polo A,
Rodriguez Vazquez M,
Martell Claros N,
FernandezCruz A
Publication year - 1984
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1984.tb02355.x
Subject(s) - atenolol , blood pressure , essential hypertension , platelet , medicine , beta (programming language) , platelet aggregation , blood lipids , beta blocker , pharmacology , adrenergic receptor , cholesterol , endocrinology , receptor , heart failure , computer science , programming language
beta‐adrenoceptor blocking agents are widely used as treatment of essential hypertension. We studied the action of a new non cardioselective beta‐adrenoceptor blocker, mepindolol, comparing its effects on blood pressure, blood lipids and platelet aggregation with those of a cardioselective beta‐adrenoceptor blocker, atenolol. Blood pressure fell significantly in the patients treated with both drugs. Triglycerides rose non‐significantly only in volunteers treated with mepindolol. We did not find any significant changes in cholesterol, free fatty acids, lipoproteins and platelet aggregation.